CeriBell (NASDAQ:CBLL) outlined its recent progress and 2026 priorities at a JPMorgan MedTech event, emphasizing continued growth in acute-care seizure detection and an expanding roadmap for ...
From prayer times to family vigils, everyday realities can alter how delirium presents — and how clinicians should respond.
Roughly 25 percent of dementia patients were prescribed at least one ‘potentially inappropriate’ drug between 2013 and 2021 ...
The Mirror US on MSN
New study finds dementia patients have been prescribed drugs that can cause delirium
Researchers are sounding the alarm on dangerous stimulant medications commonly prescribed to dementia patients in the U.S.
The Sunnyvale, CA-based firm's EEG-based solution uses artificial intelligence algorithms to identify large vessel occlusion ...
Issued on behalf of VentriPoint Diagnostics Ltd. Dana Friesen, CEO of Summit Sciences, brings over 15 years of experience in financial analysis and ROI optimization within the medical device and ...
Ceribell announced today that the FDA granted breakthrough device designation for its large vessel occlusion (LVO) stroke ...
Roughly 25 percent of dementia patients were prescribed at least one ‘potentially inappropriate’ drug between 2013 and 2021 ...
Medical Device Network on MSN
FDA grants breakthrough designation to Ceribell’s stroke detection tool
Ceribell’s LVO Stroke tool is underpinned by the same EEG monitoring technology used in its seizure and delirium monitoring ...
News-Medical.Net on MSN
Vaccines are helping older people more than we knew
The primary reason to be vaccinated against shingles is that two shots provide at least 90% protection against a painful, ...
Ceribell wins FDA Breakthrough status for its AI-driven EEG solution to detect and monitor LVO strokes in hospitals, boosting credibility and growth outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback